Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13786953 | 0.94 | MAPT (0.46) | MAPTMEN1KMT2AMAPK1TDP1 | |
| SCHEMBL19275596 | 0.83 | MAPT (0.41) | MAPTMEN1KMT2AMAPK1TDP1 | |
| SCHEMBL31192035 | 0.78 | CA12 (0.49) | MAPTMEN1KMT2AMAPK1TDP1 | |
| SCHEMBL2981356 | 0.78 | CA12 (0.49) | MAPTMEN1KMT2AMAPK1TDP1 | |
| SCHEMBL4353987 | 0.77 | MAPT (0.61) | MAPTMEN1KMT2ACA12CA9 | |
| SCHEMBL4353983 | 0.77 | MAPT (0.61) | MAPTMEN1KMT2ACA12CA9 | |
| SCHEMBL17903073 | 0.76 | CA12 (0.45) | MAPTMEN1KMT2AMAPK1TDP1 | |
| SCHEMBL10061888 | 0.76 | ASF1A (0.50) | MAPTMEN1KMT2ACA12CA1 | |
| SCHEMBL2031546 | 0.74 | KCNMA1 (0.54) | MAPTMAPK1POLBNPC1HTT | |
| SCHEMBL10061898 | 0.74 | PPARA (0.53) | MAPTMEN1KMT2ATDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034851-B2 | Metal-salen complex compound, local anesthetic and antineoplastic drug | IHI CORPORATION (JP) | 2018-07-31 | — | — | US | disclosed |
| US-10034941-B2 | Iron-salen complex | IHI CORPORATION (JP) | 2018-07-31 | — | — | US | disclosed |
| US-10030039-B2 | Anti-cancer agent and cancer cell killing method | IHI CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-9779862-B2 | Magnetic substance and magnetic substance manufacturing method | IHI CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20170240581-A1 | ANTI-CANCER AGENT AND CANCER CELL KILLING METHOD | ISHIKAWA, YOSHIHIRO (JP) | 2017-08-24 | — | — | US | disclosed |
| US-9603940-B2 | Metal salen complex derivative and process for production thereof | IHI CORPORATION (JP) | 2017-03-28 | — | — | US | disclosed |
| US-9505732-B2 | Auto magnetic metal salen complex compound | IHI CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| US-9469668-B2 | Magnetic substance | IHI CORPORATION (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20160263074-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | ISHIKAWA YOSHIHIRO (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20160193337-A1 | IRON-SALEN COMPLEX | ISHIKAWA, YOSHIHIRO (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20150028250-A1 | MAGNETIC COMPOSITION AND ITS PRODUCTION METHOD | IHI CORPORATION (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8933118-B2 | Anti-brain-tumor drug | IHI CORPORATION (JP) | 2015-01-13 | — | — | US | disclosed |
| US-20140235883-A1 | ELECTRIC DOUBLE LAYER CAPACITOR MATERIAL | IHI CORPORATION (JP) | 2014-08-21 | — | — | US | disclosed |
| US-20140206635-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | IHI CORPORATION (JP) | 2014-07-24 | — | — | US | disclosed |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | IHI CORPORATION (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20140011032-A1 | METAL-SALEN COMPLEX COMPOUND AND METHOD FOR PRODUCING THE SAME | IHI CORPORATION (JP) | 2014-01-09 | — | — | US | disclosed |
| US-20130131367-A1 | ANTI-BRAIN-TUMOR DRUG | IHI CORPORATION (JP) | 2013-05-23 | — | — | US | disclosed |
| US-20130090539-A1 | FLUOROCHROME MATERIAL AND METHOD FOR USING THE SAME | IHI CORPORATION (JP) | 2013-04-11 | — | — | US | disclosed |
| US-20130029399-A1 | METAL SALEN COMPLEX DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | YOSHIHIRO ISHIKAWA (JP) | 2013-01-31 | — | — | US | disclosed |
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | YOSHIHIRO ISHIKAWA (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131367-A1 | ANTI-BRAIN-TUMOR DRUG | SLC30A5, SLC40A1, AIFM2 | MAPT 754/4885MEN1 84/4885KMT2A 1606/4885 |
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | SDHB, SDHA, SLC40A1 | MAPT 55/4885MEN1 9/4885KMT2A 1797/4885 |
| US-20140206635-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | NCLN, KCNN2, NCSTN | MAPT 207/4885MEN1 435/4885KMT2A 1547/4885 |
| US-10034851-B2 | Metal-salen complex compound, local anesthetic and antineoplastic drug | NCLN, KCNN2, NCSTN | MAPT 207/4885MEN1 435/4885KMT2A 1547/4885 |
| US-10034941-B2 | Iron-salen complex | SLC40A1, SDHB, TFRC | MAPT 1228/4885MEN1 440/4885KMT2A 3700/4885 |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | SSBP1, KCNN1, IMMT | MAPT 198/4885MEN1 74/4885KMT2A 2649/4885 |
| US-20130029399-A1 | METAL SALEN COMPLEX DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | NCLN, SPEN, SSBP1 | MAPT 1878/4885MEN1 1038/4885KMT2A 2367/4885 |
| US-20130090539-A1 | FLUOROCHROME MATERIAL AND METHOD FOR USING THE SAME | MB, FECH, TFRC | MAPT 1202/4885MEN1 260/4885KMT2A 2305/4885 |
| US-20170240581-A1 | ANTI-CANCER AGENT AND CANCER CELL KILLING METHOD | BOD1L1, NUMA1, BUB1 | MAPT 3320/4885MEN1 377/4885KMT2A 3453/4885 |
| US-20160263074-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | NCLN, KCNN2, NCSTN | MAPT 207/4885MEN1 435/4885KMT2A 1547/4885 |
| US-20160193337-A1 | IRON-SALEN COMPLEX | SLC40A1, SDHB, TFRC | MAPT 1228/4885MEN1 440/4885KMT2A 3700/4885 |
| US-10030039-B2 | Anti-cancer agent and cancer cell killing method | BOD1L1, NUMA1, BUB1 | MAPT 3320/4885MEN1 377/4885KMT2A 3453/4885 |
| US-20140011032-A1 | METAL-SALEN COMPLEX COMPOUND AND METHOD FOR PRODUCING THE SAME | SNRNP200, MB, SDHB | MAPT 408/4885MEN1 236/4885KMT2A 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.